161 related articles for article (PubMed ID: 34638406)
1. Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma.
Puig N; Flores-Montero J; Burgos L; Cedena MT; Cordón L; Pérez JJ; Sanoja-Flores L; Manrique I; Rodríguez-Otero P; Rosiñol L; Martínez-López J; Mateos MV; Lahuerta JJ; Bladé J; San Miguel JF; Orfao A; Paiva B
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638406
[TBL] [Abstract][Full Text] [Related]
2. The
Vigliotta I; Armuzzi S; Barone M; Solli V; Pistis I; Borsi E; Taurisano B; Mazzocchetti G; Martello M; Poletti A; Sartor C; Rizzello I; Pantani L; Tacchetti P; Papayannidis C; Mancuso K; Rocchi S; Zamagni E; Curti A; Arpinati M; Cavo M; Terragna C
Front Oncol; 2022; 12():1001048. PubMed ID: 36276072
[TBL] [Abstract][Full Text] [Related]
3. Flow Cytometric Analysis of Bone Marrow Particle Cells for Measuring Minimal Residual Disease in Multiple Myeloma.
Jiang D; Zhang Y; Tan S; Liu J; Li X; Zhang C
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230860
[TBL] [Abstract][Full Text] [Related]
4. B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients.
Mendonça de Pontes R; Flores-Montero J; Sanoja-Flores L; Puig N; Pessoa de Magalhães RJ; Corral-Mateos A; Salgado AB; García-Sánchez O; Pérez-Morán J; Mateos MV; Burgos L; Paiva B; Te Marvelde J; van der Velden VHJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; Durie B; van Dongen JJM; Maiolino A; Sobral da Costa E; Orfao A
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916787
[TBL] [Abstract][Full Text] [Related]
5. Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma.
Bai Y; Chim CS
Hematology; 2019 Dec; 24(1):533-537. PubMed ID: 31280705
[TBL] [Abstract][Full Text] [Related]
6. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index.
Óskarsson JÞ; Rögnvaldsson S; Thorsteinsdottir S; Aspelund T; Gunnarsson SB; Hákonardóttir GK; Sigurðardóttir GÁ; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Sigurðsson JK; Eyþórsson E; Jónsson Á; Viðarsson B; Önundarson PT; Agnarsson BA; Pálmason R; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Harding S; Flores-Montero J; Orfao A; Durie BGM; Love TJ; Kristinsson SY
Blood Cancer J; 2023 Dec; 13(1):177. PubMed ID: 38040702
[TBL] [Abstract][Full Text] [Related]
7. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
9. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
10. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Maurillo L; Buccisano F; Spagnoli A; Del Poeta G; Panetta P; Neri B; Del Principe MI; Mazzone C; Consalvo MI; Tamburini A; Ottaviani L; Fraboni D; Sarlo C; De Fabritiis P; Amadori S; Venditti A
Haematologica; 2007 May; 92(5):605-11. PubMed ID: 17488683
[TBL] [Abstract][Full Text] [Related]
12. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
[TBL] [Abstract][Full Text] [Related]
13. What to do with minimal residual disease testing in myeloma.
Manasanch EE
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
[TBL] [Abstract][Full Text] [Related]
14. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S
Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.
Yamamoto N; Kozaki A; Hartomo TB; Yanai T; Hasegawa D; Kawasaki K; Kosaka Y; Matsuo M; Hirase S; Mori T; Hayakawa A; Iijima K; Nishio H; Nishimura N
Oncol Lett; 2015 Nov; 10(5):3228-3232. PubMed ID: 26722317
[TBL] [Abstract][Full Text] [Related]
17. [Application of CD123 in detection of minimal residual disease in acute promyelocytic leukemia].
Wang YZ; Chang Y; Zhu HH; Qin YZ; Li JL; Fu JY; Li LD; Chen SS; Huang XJ; Lu DP; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):427-32. PubMed ID: 16800913
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of lymphocyte patterns in multiple myeloma patients after autologous transplant.
Stork M; Bezdekova R; Kralova R; Sandecka V; Adam Z; Krejci M; Boichuk I; Knechtova Z; Brozova L; Sevcikova S; Rihova L; Pour L
Neoplasma; 2021 May; 68(3):519-527. PubMed ID: 33618517
[TBL] [Abstract][Full Text] [Related]
19. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry.
Farahat N; Morilla A; Owusu-Ankomah K; Morilla R; Pinkerton CR; Treleaven JG; Matutes E; Powles RL; Catovsky D
Br J Haematol; 1998 Apr; 101(1):158-64. PubMed ID: 9576196
[TBL] [Abstract][Full Text] [Related]
20. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
